 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as:Reduced side effects;Enhanced weight loss;Improved health outcomes for diabetes and other conditions;Improved oral...

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD

Lexaria Bioscience (NASDAQ:LEXX  Get Free Report) and Cardiff Oncology (NASDAQ:CRDF  Get Free Report) are both small-cap medical companies, but which is the better business? We will...

Lexaria Bioscience (NASDAQ:LEXX) versus Cardiff Oncology (NASDAQ:CRDF) Head to Head Review

Lexaria Bioscience Corp. (NASDAQ:LEXX  Free Report)  Analysts at Zacks Small Cap dropped their FY2023 earnings per share (EPS) estimates for Lexaria Bioscience in a report issued on...

Lexaria Bioscience Corp. (NASDAQ:LEXX) to Post FY2023 Earnings of ($1.03) Per Share, Zacks Small Cap Forecasts

KELOWNA, BC / ACCESSWIRE / August 30, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is...

Lexaria Provides Update on Investigational New Drug Application Progress

Check out Jim Simons Stock Picks &raquo;

 Download GuruFolio Report of Jim Simons (Updated on 08/22/2023)Related Stocks: LEXX, SILO, LIXT, NAS:LIXT...

Lexaria Bioscience Corp: A Comprehensive Stock Price Change Analysis

DehydraTECH-Nicotine reaches maximum blood saturation levels faster than world-leading brands from Swedish Match and Altria in human study NIC-H22-1Noteworthy superior subjective performance characteristics also observedKELOWNA, BC / ACCESSWIRE / August 9, 2023 / Lexaria Bioscience Corp...

Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Lexaria Bioscience (LEXX Research Report), with a ... In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Lexaria Bioscience (LEXX &#8211...

Maxim Group Sticks to Their Buy Rating for Lexaria Bioscience (LEXX)

KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp...

Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study

Maxim Group assumed coverage on shares of Lexaria Bioscience (NASDAQ:LEXX  Free Report) in a research report sent to investors on Friday morning, MarketBeat reports. The firm issued a buy...

Lexaria Bioscience (NASDAQ:LEXX) Earns Buy Rating from Analysts at Maxim Group

More countries are banning e-cigarettes as novel oral products gain tractionKELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms announces it has been granted a...

Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs encompassing fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Watchers	2,720
52-Wk Low	$0.6488
52-Wk High	$3.60

Market Cap	$7.69M
Volume (M)	30,607.00
52-Wk High	$3.60
52-Wk Low	$0.6488

LEXX Lexaria Bioscience Corp

About

Feed

News

Fundamentals